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Abstract
Self-injurious behavior is a common problem in many developmental disorders. The neurobiology
of this behavior is not well understood, but the differing behavioral manifestations and associations
with different disorders suggest that the underlying biological mechanisms are heterogeneous. The
behavioral and biological heterogeneity is also evident in several animal models, where different
manifestations can be provoked under different experimental conditions. Identifying commonalities
among the different mechanisms is likely to be helpful in the design of treatments useful for the
broadest populations of patients. The current studies reveal that nifedipine suppresses self-injurious
behavior in 4 unrelated animal models: acute administration of high doses of ± BayK 8644 or
methamphetamine in mice, dopamine agonist treatment in rats with lesions of dopamine pathways
during early development and repeated administration of pemoline in rats. The effect of nifedipine
does not appear to be due to nonspecific mechanisms, such as sedation, since other classes of
behaviors are unaffected or exaggerated. These results suggest that nifedipine may target a common
biological mechanism in the expression of self-injurious behavior, and they suggest it should be
considered in the treatment or self-injury in humans.
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Introduction
Self-injurious behavior (SIB) in humans is characterized by acts such as head banging, eye
poking, biting the digits or limbs, self-hitting, hair pulling, skin picking and others [Schroeder
et al., 2001). These behaviors occur in a number of different developmental disorders. They
are most common in mental retardation and autism, but they also occur in specific neurogenetic
syndromes such as Lesch-Nyhan disease (Anderson and Ernst, 1994; Robey et al., 2003] and
Prader-Willi syndrome [Symons et al., 1999].
The biological basis of SIB is not well understood, and the treatment is challenging. The many
different manifestations and the associations with many different disorders suggest that the
underlying neurobiological mechanisms are heterogeneous. In this setting the design of rational
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therapies useful in the broadest populations of patients may benefit from identifying shared
biological mechanisms.
Several animal models have been developed to study the biology of SIB. It has long been known
that SIB emerges in a variety of species treated with high doses or chronic administration of
psychostimulants, including amphetamine [Huberman et al., 1977; Mueller et al., 1982; Sokol
et al., 1991; Kratofil et al., 1996], methamphetamine (Kita et al., 2000; Kasim and Jinnah,
2002; Halladay et al., 2003] and pemoline [Mueller and Nyhan, 1982; Mueller et al., 1986;
King et al., 1995, 1998; Cromwell et al., 1999; Kies and Devine, 2004]. These behaviors are
often preceded or accompanied by hyperactive locomotor behavior and multiple stereotypical
behaviors such as grooming and licking. The mechanisms responsible for SIB in the
psychostimulant models remain incompletely understood but are likely to involve their ability
to stimulate the release of monoamines in the brain. In fact SIB also results from direct
microinjection of amphetamine into the striatum of rats, suggesting a release of dopamine in
this region to play a key role [Kelley et al., 1988, 1989; Dickson et al., 1994].
SIB may also occur after chronic delivery of very high doses of caffeine and theophylline in
mice and rats [Mueller et al., 1982; Kies and Devine, 2004]. The mechanism responsible for
SIB in this model is poorly understood but thought to involve disruption of dopaminergic or
adenosinergic systems in the striatum [Jinnah et al., 1990]. Another well-studied animal model
for SIB involves making lesions of brain dopaminergic pathways with the toxin 6-
hydroxydopamine (6OHDA) during early postnatal development in rats, followed by
pharmacological challenge with dopamine agonists after 1 month of age [Breese et al, 2004].
Rats treated in this way develop hyperactivity, multiple stereotypical behaviors and SIB.
Extensive studies of this model have led to the conclusion that SIB results from overstimulation
of striatal dopamine receptors that have been sensitized by dopamine depletion and subsequent
agonist challenges.
More recently SIB has been shown to occur in mice and rats after administration of ± BayK
8644, an activator of voltage-regulated (L-type) calcium channels [Jinnah et al., 1999; Kasim
et al., 2002; Kasim and Jinnah, 2003]. Unlike the psychostimulant or 6OHDA models, SIB in
this model emerges within minutes after the first dose and is accompanied by dystonic motor
behavior rather than stereotypical behaviors. Further studies of this model have indicated that
striatal dopamine receptors play a role in the expression of SIB in this model and that SIB can
be markedly attenuated by nifedipine, an L-type calcium channel antagonist [Jinnah et al.,
1999; Kasim and Jinnah, 2003; Kasim et al., 2006].
SIB is a complex behavior that is likely to involve abnormal function or interaction among
multiple cortical and subcortical brain regions. The observation that many animal models for
SIB share the common feature of dysfunction of striatal dopamine pathways suggests that these
pathways are involved in the neural systems generating SIB. Dysfunction of these pathways
is also thought to underlie SIB in several human conditions [Visser et al., 2000]. At the
biochemical level, the observation that striatal dopamine receptors are coupled to L-type
calcium channels suggests the possibility that these channels might serve as a common
mechanistic link for the expression of SIB. If this is the case, blockers of these channels might
suppress SIB in many different animal models. We therefore tested the ability of nifedipine to
suppress SIB in 4 different animal models.
Methods
Experimental Strategy
The goal of these experiments was to assess the efficacy of nifedipine for suppressing SIB
across 4 different animal models, each involving very different methods. The models included
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subcutaneous administration of ± BayK 8644 or methamphetamine mice, repeated daily
administration of pemoline in rats and dopamine agonist challenge in rats with prior 6OHDA
lesions. The caffeine model of SIB was not evaluated because of concerns related to its
profound behavioral toxicity [Kasim and Jinnah, 2002; Kies and Devine, 2004]. Each model
was tested independently by an experienced research group, according to methods previously
established for producing the most robust and reliable expression of SIB in the model.
No attempt was made to force the models to conform to specific standardized conditions
including animal species, age or sex. As a result rigorous quantitative comparisons among the
groups were not feasible. The main focus of these studies was on SIB; changes in ancillary
behaviors were collected and presented only where they were useful to demonstrate specificity
of behavioral effects.
Animals
All animals were housed with free access to food and water, and all experimental procedures
were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and
were approved by the Animal Care and Use Committee of the appropriate institution. In order
to prevent unnecessary pain and suffering, significant SIB was terminated whenever it occurred
by the administration of 20 mg/kg of nifedipine or a sedative.
The ±BayK 8644 model has been characterized in young C57BL/6J mice, where SIB occurs
without bias according to sex. This model therefore included 4-week-old male and female mice
of this mouse strain. The expression of SIB in the methamphet-aminc model depends on mouse
strain, sex and housing conditions. The conditions selected to optimize expression of SIB for
this model involved the use of the Balb/c mouse strain, male sex and isolation housing for 1
week. The 6OHDA and pemoline models have both been best characterized in rals, with little
or no data available for mice. These models were therefore tested using rats rather than mice.
The strain of rat was chosen according to the preferences of the test site.
± BayK 8644 Model
Normal C57BL/6J mice were obtained from the Jackson Laboratories (Bar Harbor, Me., USA)
and bred and maintained at Johns Hopkins University in groups of 2–12 with free access to
food and water at all times. ±BayK 8644 was obtained from Sigma-RBl (St. Louis, Mo., USA),
and a stock solution of 10 mg/ml was prepared by dissolving in a mixture containing equal
parts of ethanol and Tween-80. The stock was stored in amber vials at 4°C for up to 1 month
and freshly diluted with distilled water immediately before it was used at a total volume of 10
ml/kg.
Independent groups of drug-naïve C57BL/6J mice each received 2, 4, or 8 mg/kg of ± BayK
8644. Five minutes prior to the ±BayK 8644 injections, half of each ±BayK 8644 dose group
received a subcutaneous injection of 20 mg/kg of 1 of 5 calcium channel antagonists, while
the other half received subcutaneous injections of vehicle as controls. The behaviors were
assessed as previously described [Kasim et al., 2002, 2006; Kasim and Jinnah, 2003]. The
animals were observed for 1 min every 10 min for 1 h immediately following ±BayK 8644
administration, and their behaviors were recorded. Self-biting (SB) was denned as biting any
portion of the body without tissue injury, while SIB was defined as biting that resulted in tissue
injury. The frequencies of these behaviors were analyzed using the χ2 statistic for
nonparametric measures.
Methamphetamine Model
Balb/c mice were obtained from the Jackson Laboratories at 5–6 weeks of age and housed
singly at Johns Hopkins University for 1 week prior to behavior testing. SB and SIB in response
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to methamphetamine depends on strain, sex and housing conditions [Kasim and Jinnah,
2002; Halladay et al., 2003]. To maximize the expression of these behaviors, only male Balb/
c mice were evaluated after 1 week of isolation housing.
Methamphetamine was obtained from Sigma-RBI, dissolved in saline and injected
subcutaneously at a dose of 10 mg/kg. In the first experiment half of the mice were
simultaneously treated with 5 mg/kg of nifedipine. This experiment was repeated in a second
experiment with a fresh group of mice, half of which received 10 mg/kg of nifedipine. In a
third experiment half the mice received 20 mg/kg of nifedipine.
SB, SIB and other stereotypical behaviors (sniffing, licking and grooming) were evaluated as
previously described [Kasim and Jinnah, 2002; Halladay et al., 2003]. Immediately after
injection each mouse was observed for 1 min every 15 min for 90 min. The frequencies of
SBand SIB were recorded, and the average percentage of time the animals engaged in each
stereotypical behavior was estimated by averaging the 6 recording intervals and analyzed using
ANOVA.
6OHDA Model
Pregnant Sprague-Dawley rats were obtained from Harlan (Indianapolis, Ind., USA) and
housed at the University of North Carolina. Male and female neonates were pretreated with 20
mg/kg of desipramine subcutaneously at 3–5 days of age to block the uptake of 6OHDA into
noradrenergic neurons. Approximately 60 min later, they were anesthetized with ether and
given intracisternal injections of 100 μg of 6OHDA (free base) freshly dissolved in 10 μ1 of
saline with 0.01% ascorbic acid. This treatment results in >95% loss of dopamine and its axons
in the striatum [Papadeas et al., 2004].
The behavioral observations began at 40 days of age. Apomorphine and nifedipine (Sigma-
RBI) were prepared fresh on each day. To assess the sensitivity to apomorphine-mediated SB.
rats lesioned as neonates were injected with vehicle (dimethylsulfoxide for nifedipine)
intraperitoneally. Ten minutes later they were given a subcutaneous injection of apomorphine
at 10 mg/kg in saline. One week later the same animals were administered 5, 10 or 20 mg/kg
of nifedipine 10 min prior to 10 mg/kg of apomorphine. The rats were observed for 1 min every
10 min for 90 min, and the frequencies of SB and SIB were analyzed as described above. The
percentage of time the rats engaged in various stereotypical behaviors was also estimated at
each interval.
Pemoline Model
Male Long-Evans rats (Charles River Laboratories, Raleigh, N.C., USA) were pair-housed in
standard polycarbonate cages (43 × 21.5 × 25.5 cm) during 5–7 days of acclimation to the
housing facility. They were tested at 2 months of age. They were singly housed in standard
polycarbonate cages during the experimental procedures.
Pemoline (Spectrum Chemicals, New Brunswick, N.J., USA), and nifedipine (Sigma-RBI)
suspensions were prepared fresh on each day. The pemoline was suspended at a concentration
of 50 mg/ml in warm peanut oil (held at 37°C) with constant stirring. The rats were injected
subcutaneously with 200 mg/kg of pemoline at approximately 8.00 a.m. on each of 5
consecutive days. Nifedipine was suspended at concentrations of 0, 1.5, 5 and 15 mg/ml in a
solution consisting of 40% propylene glycol, 10% ethanol, 15% benzyl alcohol and 35%
distilled water. The rats were injected twice daily with nifedipine (0, 3, 10 or 30 mg/kg s.c.)
on each of the 5 days (n = 5–6 per group). The nifedipine injections were administered
immediately after the pemoline injections and at approximately 6.00 p.m.
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In this model SB and SIB evolve more slowly than in the other models. As a result a different
method for behavioral assessment was required [Kies and Devine, 2004]. SIB was evaluated
by estimating the time the animals engaged in self-injurious oral contact and by scoring the
severity of tissue injury. Self-injurious oral contact was defined as contact between the mouth
and any body part, where contact stayed fixed on that body part for longer than 2 s, to
differentiate it from grooming. It was recorded in 5-min time samples every hour for 8 h each
night using night vision cameras. The videotapes were scored, and the duration of self-injurious
oral contact was calculated as percentage of the total time sampled.
Tissue injury was also examined in each rat, each time it was injected (i.e. twice per day for 5
days). These examinations consisted of visual inspection of each rat's head, forepaws, ventrum
(ventral thorax and abdomen), hindpaws and tail, and each examination was videotaped. An
injury score (table 1) was assigned to describe the presence (or absence) and severity of all
injuries. These examinations were also performed on the morning of the sixth day, but no
injections were administered. Immediately after this final inspection each rat was terminated.
The tissue injury was then independently rescored from the videotape recordings by a trained
observer, who was blind to the experimental conditions. The interexperimenter reliability was
94%, and in the 6% of cases where the experimenters' ratings differed, they never differed by
more than 1 point on the rating scale.
Grooming, inactivity and locomotion were also scored from the videotaped time samples.
Grooming was defined as oral contact that continuously moved from one body part to another
(i.e. the contact was not sustained on any specific body part for longer than 2 s). Inactivity was
defined as a complete lack of movement except respiratory movements, and the duration of
groomingand inactivity were each calculated as percentages of the total time sampled.
Locomotion was counted by sectioning the cage into 3 equal parts (along the length of the
cage) and counting (he number of limes the rat crossed into a different section without returning
to the section that it had occupied immediately prior to that movement.
Some rats were euthanized before the end of the experiment because they had an injury score
of 4 (open lesion). In these cases the missing data were replaced by repeating the final scores
that were recorded through to the end of the experiment. This strategy was used to avoid the
potential that the group means would underestimate the self-injurious oral contact and tissue
injury scores when the severest self-injurers were removed from any group. Between-group
differences in self-injurious oral contact, tissue injury scores, grooming, inactivity and
locomotion were each evaluated using repeated measures ANOVA. All significant effects were
further analyzed with LSD posttests.
Results
BayK 8644 Model
Increasing doses of ±BayK 8644 alone led to higher frequencies of both SB and SIB in the
vehicle-treated controls as previously reported [Jinnah et al., 1999; Kasim et al., 2002, 2006;
Kasim and Jinnah, 2002, 2003], with most mice exhibiting SB and SIB after the highest dose
(fig. 1). Pretrcatment with nifedipine resulted in a marked suppression of SB and complete
elimination of SIB at all doses of BayK 8644 (fig. 1).
To determine if other L-type calcium channel antagonists might have similar effects, additional
groups of drug-naive mice were used to lest 5 other calcium channel antagonists in the same
manner. Prctreatment with nitrendipine also significantly suppressed SB in response to ±BayK
8644 (fig. 1). Nitrendepine produced a trend for reduced SIB that was not statistically
significant. No significant reduction of SB or SIB was apparent following prelreatments with
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nimodipine, amlodipine, diltiazem or verapamil. These results indicate that only some L-type
calcium channel antagonists can suppress SB and SIB.
Methamphetamine Model
Further studies of other animal models of SB and SIB focused on nifedipine, since it seemed
to have the greatest impact on these behaviors in the ±BayK 8644 model. Independent groups
of drug-naive Balb/c mice each received subcutaneous injection of 5 mg/kg of nifedipine or
vehicle, immediately followed by 10 mg/kg of methamphetamine. The administration of 10
mg/kg of methamphetamine alone induced SB in a high proportion of mice, with a small
proportion progressing to SIB (table 2). Pretreatment with 5 mg/kg of nifedipine suppressed
SB and eliminated SIB in response to methamphetamine.
Additional groups of drug-naïve mice were used to evaluate the effects of higher nifedipine
pretreatment doses (10 or 20 mg/kg) on melhamphctamine-induced SB and SIB. These higher
doses of nifedipine resulted in an even greater suppression of SB and again eliminated SIB, in
response to methamphetamine (table 2).
Pretreatment with nifedipine also influenced other stereotypical behaviors (fig. 2). Taffy
pulling, a repetitive hand-mouth behavior that often precedes SIB, was significantly reduced
by nifedipine. Other stereotypical behaviors, such as sniffing or licking the cage, were
increased. These results argue that nifedipine does not exert a nonspecific suppression of all
behaviors (e.g. sedation) but rather modifies the profile of behaviors.
60HDA Model
The susceptibility of thelesioned rats to exhibit SB and SIB was first verified by administering
vehicle intraperitoneally, followed by 10 mg/kg of apomorphine subcuta-neously 10 min later.
The vehicle pretreatment was repeated for each experiment involving 1 of 3 doses of nifedipine.
Behavioral observations made over 90 min following apomorphine injection revealed that 84%
of all vehicle-pretreated rats lesioned as neonates engaged in SB (38 of 45), while 67% (30 of
45) exhibited SIB. These findings are in close accordance with previous results using L-dopa
rather than apomorphine [Breese et al., 1984].
One week after the vehicle-apomorphine pretreatments, the rats were injected with 5, 10 or 20
mg/kg of nifedipine, followed by 10 mg/kg of apomorphine 10 min later. Nifedipine attenuated
both SB and SIB (table 3). Among the animals that bit themselves during the 90-min
observation period, there was a delayed onset of SB in both the 10- and 20-mg/kg nifedipine
groups (not shown).
Nifedipine also modified the expression of other stereotypical behaviors in this model. Taffy
pulling was decreased, whereas sniffing or gnawing/licking the cage wall were increased.
These observations suggest a change in the topography of behaviors rather than a global
suppression of all behaviors {fig. 3).
Pemoline Model
The daily treatment of the rats with pemoline led to a progressive increase in the severity of
SB and SIB expressed as the duration of self-injurious oral contact or the severity of tissue
injury (fig. 4) as previously described [Kies and Devine, 2004]. The treatment with nifedipine
(3,10 or 30 mg/kg b.i.d. for 5 days) significantly lessened the duration of pemoline-induced
self-injurious oral contact and the severity of tissue injury across the days of the experiment.
Nifedipine did not significantly affect any of the other measured behaviors, including
grooming, time inactive or the amount of locomotion (fig. 5).
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SIB in humans lias many different clinical manifestations. For specific and well-defined causes
of the behavior, the manifestations are relatively stereotyped. Examples include stereotypical
skin picking in Prader-Willi syndrome, recurrent biting in Lesch-Nyhan disease and head
banging in autism [Symons et al., 1999; Schroeder et al, 2001; Robey et al., 2003; Schretlen
et al., 2005]. The more stereotyped patterns of SIB in the well-defined disorders suggest that
the differing clinical manifestations are in part due to differing etiologies. The heterogeneity
of the underlying causes makes finding universally useful treatments challenging because the
treatment must simultaneously address multiple different biological mechanisms. In this
situation the identification of shared neural pathways or common biochemical mechanisms
holds great promise for identifying potential new therapies.
Animal models that express SIB can be useful for investigating underlying biological
mechanisms and for preliminary screening of potential new therapies. Similar to humans, SIB
in animals has many different manifestations. For example, biting is the most common form
of SIB, but the topography differs among the models. The forepaws and digits are the most
frequent targets in many of the models, whereas the vent rum or tail are frequent targets in the
caffeine model [Mueller et al., 1982; Kies and Devine, 2004]. The temporal profile of SIB also
differs among the models. It evolves slowly over days with chronic treatment in the pemoline
and caffeine models [Mueller et al., 1982; Kies and Devine, 2004], requires repeated daily
challenges in the neonatal 60HDA model [Breese et al., 2004] and occurs within minutes in
the ±BayK model [Jinnah et al., 1999; Kasim and Jinnah, 2003]. The comorbid behaviors also
differ. The stereotypies are universal in the psychostimulant and neonatal 60HDA models, less
prominent in the caffeine model and absent in the ±BayK model [Kasim and Jinnah, 2002;
Kies and Devine, 2004].
The biological mechanisms underlying SIB also differ among the animal models. The
psychostimulant and neonatal 60HDA models involve dopaminergic mechanisms, whereas the
BayK 8644 model involves calcium channels. Recent studies have shown a link between the
calcium channels influenced by BayK 8644 and dopamine receptors, though the ability of BayK
8644 to provoke SIB does not require presynaptic dopamine or postsynaptic dopamine receptor
integrity [Kasim and Jinnah, 2003; Kasim et al., 2006]. The mechanisms underlying the
caffeine model remain uncertain because the high doses needed obscure pharmacological
specificity [Jinnah et al., 1990].
The ability of nifedipine to suppress SIB in multiple animal models is noteworthy, considering
the differing manifestations and underlying causes. Nifedipine does not suppress all behaviors
in these models and in fact increases certain classes of stereotypical behaviors, such as
repetitive sniffing, in themcthamphetamine and 60H DA models. These observations suggest
that nifedipine does not suppress SIB by nonspecific mechanisms such as sedation. The
mechanisms by which nifedipine suppresses SIB will require further investigation. Nifedipine
is best known for its ability to block L-type voltage-regulated calcium channels, which are
widely expressed in the brain and body [Jinnah et al., 2004]. It seems feasible that the channels
linked with striatal dopamine pathways could play a role in a shared pathway in the expression
of SIB [Kasim et al.,2006].
If L-type calcium channels play a role in the expression of SIB, other antagonists of these
channels should have the same beneficial effects as nifedipine. This prediction was evaluated
in the ±BayK 8644 model for SIB by evaluating 5 other drugs. Nitrendipine was indeed
effective in suppressing SB with a trend for reducing SIB, but 4 other calcium channel
antagonists were not (nimodipine, amlodipine, diltiazem and verapamil). The reasons for the
lack of uniform efficacy are not clear, though several possibilities could be considered.
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Somedrugs (verapamil) do not cross the blood-brain barrier, limiting the access to relevant
neural pathways. Other drugs (amlodipine) exhibit an idiosyncratic state-dependent blockade
of the calcium channel, potentially limiting the efficacy under certain circumstances. Finally
the L-type calcium channels comprise multiple distinct isoforms with different tissue
distributions and different regional localizations within the brain [Hetzenauer et al., 2006]. The
available drugs may differentially influence these channel subtypes. Further studies may be
useful for clarifying the reasons for differing efficacy among the calcium channel antagonists
in the BayK 8644 model, for determining if similar patterns of efficacy exist in the other models
of SIB and for identifying related drugs with an even greater efficacy than nifedipine.
In addition to the apparent differences in efficacy among the L-type calcium channel
antagonists in the BayK 8644 model, there may also be differences in the efficacy of nifedipine
across the different models. Though strict quantitative comparisons across these models are
not possible because the data were collected by different centers using different methods, some
trends are apparent. Nifedipine eliminated SIB in the BayK 8644 and methamphetamine
models, reduced tissue injury scores by 30–50% in the pemoline model and caused a
nonsignificant trend for reduced SIB in the 60HDA model. Some of these apparent differences
in efficacy may result from purely pharmacokinetic issues. The short half-life of nifedipine
limits its effective duration to <90 min, rendering it most useful in the acute models (BayK
8644 and methamphetamine). It would be predicted to be less effective in the pemoline model,
due to the very long half-life of pemoline [Kies and Devine, 2004]. Further studies of long-
acting preparations of nifedipine or other long-acting L-type calcium channel antagonists might
help resolve this issue. Other differences in the apparent efficacy of nifedipine across the
models may be model specific. For example, full development of SIB in the 60HDA model
requires repeated dosing of apomorphine, a phenomenon known as priming [Criswell et al.,
1989]. The ability of nifedipine to suppress SIB in this model may therefore require further
studies to distinguish an effect of the drug on the behavior versus the priming process. Despite
these differences among the models, it is notable that nifedipine was at least partly effective
in reducing SB or SIB in all of them.
In humans nifedipine has not yet received much attention for SIB, but it has been used for
decades in the treatment of other disorders such as hypertension. It has proven very safe, with
no serious side effects even during chronic therapy. It has been used in both children and adults.
It has minimal central nervous system side effects such as sedation or agitation. These relatively
benign properties contrast with those of the neuroleptics, which have also been proposed for
the treatment of populations with SIB [Luchins, 1991; McDonough et al., 2000; Schroeder et
al., 2001; Breese et al., 2004]. Unfortunately a widespread adoption of neuroleptics for SIB is
not likely because of variable efficacy and several unwanted side effects. The neuroleptics are
often sedating at doses used to suppress SiB, making it difficult to separate a specific influence
on SIB from sedation. The problem of sedation is particularly challenging for populations with
comorbid mental retardation. Neuroleptics also carry a significant risk for short-term side
effects such as drug-induced parkinsonism, akathisia, acute dyslonic reactions and the
neuroleptic malignant syndrome. Most troublesome is the risk of neuroleptic-induced tardive
dyskinesia, which can be permanent and disabling. In view of the efficacy of nifedipine in
multiple animal models and its safety track record in humans, it seems an attractive candidate
for a clinical trial.
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Calcium channel antagonists suppress SB and SIB in response to ±BayK 8644. The top row
of panels shows the frequencies of SB, while the bottom row shows SIB. The calcium channel
antagonists (20 mg/kg each) are noted above the panels. The results for these antagonists are
shown as black bars, while the corresponding control group is shown in gray. Ten mice were
tested under each drug and dose condition. The results of the χ2 statistical analysis comparing
the influence of the antagonist with its corresponding control group are shown within each
panel.
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Nifedipine alters the frequency of stereotypical behaviors after a single dose of
methamphetamine. The results show the average percentage of the lime the animals spent
engaging in the behavior, expressed as a percentage of vehicle-treated controls (±SEM). With
10 mg/kg of nifedipine, SB and taffy pulling were significantly decreased, while repetitive
sniffing or licking/biting the cage walls were increased (p < 0.01).
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Nifedipine (10 mg/kg) alters the frequency of stereotypical behaviors after apomorphine
treatment of rats with neonatal 60HDA lesions. The fraction of lime that nifedipinc-prctrcatcd
raLs were observed engaging in behaviors is expressed as the average percent of vehicle-treated
rats (±SEM). Compared to vehicle, pretreatment with 10 mg/kg of nifedipine significantly
reduced the percentage of time the rats spent taffy pulling (p < 0.001) and significantly
increased the time they spent sniffing (p<0.0l). The trends towards increased gnawing/licking
the cage and reduced SB were not significant (p > 0.10).
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Nifedipine reduces SB and SIB in pemoline-treated rats. a Average duration of self-injurious
oral contact, measured as percentage of the time during which sustained oral contact occurred
during the videotaped overnight time samples, b Tissue injury scores, as measured according
to table 1. All values are expressed as group means ± SEM. Significant differences between
rals treated with vehicle or nifedipine (LSD) are depicted as follows: a p <; 0.05 for comparisons
between nifedipine at 30 mg/kg and vehicle, b p < 0.05 for comparisons between nifedipine at
10 mg/kg and vehicle, and c p < 0.05 for comparisons between nifedipine at 3 mg/kg and
vehicle.
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The effect of nifedipine on other pemoline-induced behaviors in rats. The time spent grooming
(a; F4,72 = 4.6, p < 0.01) or inactive (b; F4, 72 = 6.7, p < 0.01) and the amount of locomotion
(c; F4, 72 = 23.9, p < 0.01) recorded on videotapes overnight all decreased significantly across
the days of ilie experiment, but no significant between-group effects or group by time
interaction effects were found.
Blake et al. Page 15

























Blake et al. Page 16
Table 1
Tissue injury raling scale
Score Description
0 No injury
1 Very mild injury Denuded skin, edema or erythema;
involves small area
2 Mild injury Denuded skin, edema or erythema;
involves medium area or multiple small
areas
3 Moderate injury Denuded skin, edema or erythema;
involves large area or multiple medium
sites
4 Severe injury Open lesion, requires immediate
euthanasia
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Table 2
Methamphetamine model
Treatment group SB SIB Mortality
Experiment 1
 Methamphetamine alone 10/12 2/12 1/12
 Methamphetamine + 5 mg/kg nifedipine 5/12 0/12 0/12
Experiment 2
 Methamphetamine alone 11/12 4/12 1/12
 Methamphetamine + 10 mg/kg nifedipine 1/12 0/12 0/12
Experiment 3
 Methamphetamine alone 8/12 4/12 0/12
 Methamphetamine + 20 mg/kg nifedipine 0/12 0/12 0/12
A χ2 analysis comparing animals treated with or without nifedipine revealed significant effects on both SB (χ2 = 29.4, p < 0.001) and SIB (χ2 = 11.6,
p < 0.001).













Blake et al. Page 18
Table 3
Neonatal 6OHDA model
Treatment group SB SIB
Experiment 1
 Vehicle 10/10 6/10
 Nifedipine (5 mg/kg) 9/10 5/10
Experiment 2
 Vehicle 19/19 15/19
 Nifedipine (10 mg/kg) 16/19 10/19
Experiment 3
 Vehicle 13/16 9/16
 Nifedipine (20 mg/kg) 8/16 4/16
A χ2 analysis comparing animals treated with or without nifedipine revealed a significant effect on SB (χ2 = 5.4, p < 0.02), but the effect on SIB was
not significant (χ2 = 1.7, p = 0.2).
Dev Neurosci. Author manuscript; available in PMC 2010 October 7.
